Videos

5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

5 interviews in 5 minutes. Check out this HCPLive Five at ATS 2026 on late breaking data in sleep apnea, lung function recovery, PAH, lung disease, and COPD.

Catch up on major trial results, key FDA decisions, and more.

Delphine Kerob, MD, in this segment of her interview, expanded on the clinical implications of new data on atopic dermatitis and lifelong impacts.

At EAC 2026, Dartmouth Children's Health allergist Marcus Shaker, MD, outlined a framework built on shared decision-making for families navigating food allergy in infancy.

A study revealed adults with childhood onset atopic dermatitis may see greater limitations in career and educational options.

Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.

The latest ABCs of Dermatology explored the future potential of amlitelimab in atopic dermatitis and the potential of OX40 ligand-targeted therapy.

Marcus Shaker, MD, discusses early allergen introduction, food allergy prevention, and the role of routine testing at EAC 2026.

This interview highlights key facts regarding HS in honor of Hidradenitis Suppurativa (HS) Awareness Week, featuring Kiera Booth, MD.

This segment of the Skin of Color Savvy podcast highlights how dermatologists can improve sunscreen adherence among individuals with skin of color.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover topline data from the TRIUMPH-1 trial of retatrutide for obesity management.

This interview highlights topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with atopic dermatitis.

This episode covers the FDA’s recent approval of MannKind’s inhaled insulin Afrezza for patients aged 6-18 years with either T1D or T2D.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval of the Libre Duo and Libre Duo 10 Day monitors.

This segment of the May episode of The Medical Sisterhood highlights the importance of addressing patients' and parents' fears in dermatology.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

Heather Johnson, MD, discusses progress in providing more individualized care to female cardiovascular patients, as well as what remains to be done.

Igor Barjaktarevic, MD, discussed findings at ATS 2026, where the recombinant therapy outperformed weekly plasma-derived augmentation on key pharmacokinetic endpoints.

In a recent episode of The Medical Sisterhood podcast, Lisa Swanson, MD, spoke about the importance of female mentorship in medicine.

Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.

This episode covers Abbott’s Libre Duo and Libre Duo 10 Day systems, Eli Lilly’s retatrutide, and the recent Dexcom sensor theft.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.

This segment of the latest Skin of Color Savvy podcast highlighted persistent disparities in skin cancer prevention, awareness, and diagnosis.

At ATS 2026, Sarath Raju, MD, discussed retrospective data linking SGLT2 inhibitor use to reduced 30-day readmissions in patients hospitalized for AE-COPD and diabetes.

Ferdinand shares his advice on high blood pressure management, drawing on his perspective as co-author of the ACC/AHA 2025 hypertension guidelines.